Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: methotrexate

Biologic or Conventional Therapy for Early RA?

  |  

A study has shown that in untreated patients with early RA, treatment with methotrexate combined with the biologic therapies abatacept or certolizumab-pegol resulted in greater CDAI remission rates than active conventional therapy with prednisolone, sulfasalazine or hydroxychloroquine.

Predicting the Future: Prognostication in Rheumatoid Arthritis

  |  

A EULAR 2022 abstract session looked at several studies that seek to increase understanding of RA pathogenesis & identify patients at risk for disease progression.

Never Too Late: Late-Breaking Abstracts Create Excitement

  |  

EULAR 2022 (VIRTUAL)—The pace of scientific progress in research medicine is incredible and seems to only accelerate with time. Thus, the 2022 Congress of the European Alliance of Associations for Rheumatology (EULAR) session on late-breaking abstracts fittingly captured the excitement and timeliness of a number of research projects that have just recently been completed and…

Clinical Guidance & Recommendation Updates for Vasculitis, axSpA & More

  |  

In this EULAR 2022 session, new & revised treatment recommendations for ANCA-associated vasculitis, axial spondyloarthritis & rheumatoid arthritis were presented.

FDA Approves Riabni, a Rituxumab Biosimilar, to Treat Patients with RA

  |  

Based on findings from a double-blind, placebo-controlled study evaluating its efficacy and safety, rituximab-arrx has received FDA approval for the treatment of patients with rheumatoid arthritis.

A Prescription for Mindfulness

Dana DiRenzo, MD, MHS  |  

The prescription is a powerful tool for a physician. As rheuma­tologists, we prescribe many things—drugs, physical therapy, durable medical equipment—but what about stress reduction? We are very specific about times of day to take medications and in what manner. Patients ask: With or without food? With other medications? Before or after other prescribed medications? If…

The ACR Responds to Impact of the Dobbs v. Jackson Decision on Rheumatology Patients and Providers

Joseph Cantrell, JD, & Kenneth G. Saag, MD, MSc  |  

The ACR and a new Access to Reproductive Health Care Task Force are working to ensure patients with rheumatic disease—particularly women—have access to the medications and treatments they need, including methotrexate, and that rheumatology providers are able to maintain trusting relationships with and advise their patients on all matters relevant to the management of their rheumatic diseases.

Challenges in Reproductive Health in Rheumatic Disease

Keri Losavio & Julie Nusbaum, MD  |  

In light of new challenges to individuals’ reproductive rights and the known challenges of clinical management of rheumatic disease patients during pregnancy, we review the current state of reproductive rheumatology and the management of patients with rheumatic disease during pregnancy.

The U.S. Supreme Court

The ACR Responds to Reports of Treatment Denials in Wake of Dobbs v. Jackson Women’s Health Organization

  |  

The ACR is aware of the emerging concerns surrounding access to needed treatments, such as methotrexate, after the recent decision in Dobbs v. Jackson Women’s Health Organization. We are following this issue closely to determine if rheumatologists and rheumatology providers and patients are experiencing any widespread difficulty accessing methotrexate, and if any initial disruptions are…